Evidence map›Paper›PMID 36950102›Full record

ArticleFrontiers in public health2023

The stake of informing patients of the risk of hypofertility after chemotherapy for breast cancer.

Florian Martinet-Kosinski, Sébastien Lamy, Eric Bauvin, Florence Dalenc, Charlotte Vaysse, Pascale Grosclaude

Open access · goldFull text read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Florian Martinet-KosinskiEquity Team: Team Labeled by the French League Against Cancer, UMR1295 CERPOP, Toulouse, France.
Sébastien LamyEquity Team: Team Labeled by the French League Against Cancer, UMR1295 CERPOP, Toulouse, France.
Eric BauvinEquity Team: Team Labeled by the French League Against Cancer, UMR1295 CERPOP, Toulouse, France.
Florence DalencDepartment of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France.
Charlotte VaysseDepartment of Surgical Oncology, University Hospital Center Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Pascale GrosclaudeEquity Team: Team Labeled by the French League Against Cancer, UMR1295 CERPOP, Toulouse, France.
Université Toulouse III - Paul Sabatier · FRInstitut Claudius Regaud · FRInstitut universitaire du cancer de Toulouse Oncopole · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Too few women with invasive breast cancer are informed of the risk of hypofertility after chemotherapy. However, this risk can be prevented by offering gamete preservation by a specialized team. We believe that if more women were informed about gamete preservation, more of them would accept it. Objectives: The primary objective is to describe each step of the oncofertility care pathway from provision of information to gamete preservation. The secondary objective is to estimate the impact of not receiving information by determining the proportion of women who would have undergone gamete preservation if they had been informed. Method: 575 women aged 18-40 years treated with chemotherapy for breast cancer between 2012 and 2017 in the Ouest-Occitanie region (~3 million inhabitants) were included. We first constructed a multivariate predictive model to determine the parameters influencing the uptake of the offer of gamete preservation among women who were informed and then applied it to the population of uninformed women. Results: Only 39% of women were informed of the risks of hypofertility related to chemotherapy and 11% ultimately received gamete preservation. If all had been informed of the risk, our model predicted an increase in gamete preservation of 15.35% in the youngest women (<30 years), 22.88% in women aged between 30 and 35 years and zero in those aged ≥36 years. We did not find any association with the European Deprivation Index (EDI). Conclusion: Oncologists should be aware of the need to inform patients aged ≤ 35 years about gamete preservation. If all received such information, the impact in terms of gamete preservation would likely be major.

Indexed as

Breast NeoplasmsFertility PreservationOncologistsAdultFemaleHumansbreast cancerinformation—access and interactiononcofertilitysocial inequalitieswoman health

Identifiers

PMID36950102
PMCPMC10027074
OpenAlexW4323309327

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read68
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.